{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:09:26Z","timestamp":1793653766345,"version":"4.5.1"},"reference-count":52,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["W81XWH2210245"],"award-info":[{"award-number":["W81XWH2210245"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"United States Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Schoen Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Chronic kidney disease (CKD) is common in patients with heart failure (HF) with preserved ejection fraction (HFpEF), and its presence is associated with more severe echocardiographic abnormalities and poorer outcomes through unclear mechanisms. CKD-associated endothelial dysfunction, inflammation, and activation of profibrotic pathways could worsen pulmonary vascular disease (PVD) in HFpEF, but such relationships have not been explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Consecutively evaluated patients with HFpEF undergoing invasive haemodynamic cardiopulmonary exercise testing were stratified by baseline kidney function to characterize potential differences in pulmonary vascular loading, haemodynamics, cardiopulmonary reserve, and outcomes based upon the presence and severity of kidney dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 925 patients with HFpEF, 319 (34.5%) had estimated glomerular filtration rate (eGFR) &amp;lt; 60\u2005ml\/min\/1.73\u2005m2. Patients with more severe kidney dysfunction were older and more likely to have diabetes, atrial fibrillation, and hypertension. At rest, reduced kidney function was associated with lower haemoglobin, higher biventricular filling pressures, and lower cardiac output, but the severity of kidney dysfunction was most conspicuously associated with worsening PVD, evidenced by increasing pulmonary arterial (PA) pressures due to marked increases in pulmonary vascular resistance (PVR) as kidney dysfunction progressed (median [IQR] 1.3 [0.86, 1.88] to 2.8 [2.0, 3.8] WU from eGFR \u2265 90 to eGFR &amp;lt; 30, P &amp;lt; .001), along with progressively lower PA compliance (PAC, 4.7 [3.6, 5.8] to 2.2 [1.8, 3.4] ml\/mmHg from eGFR \u2265 90 to eGFR &amp;lt; 30, P &amp;lt; .001). With exercise, differences in the severity of PVD became even more striking, with more severe elevation in PA pressures and PVR, and lower PA compliance, leading to lower transmural left-sided distending pressures, with no difference in exertional PA wedge pressure. Patients with worse kidney dysfunction displayed the most dramatic cardiac output limitations with exercise, which along with more severe anaemia and markedly reduced O2 delivery, caused marked impairment in aerobic capacity. Worsening kidney function was associated with a striking gradient of increased risk of a composite of all-cause death and HF hospitalization [ranging from HR 2.38 (95% CI 1.01\u20135.59) for eGFR 60\u201390 to HR 16.77 (95% CI 6.65\u201342.28) for eGFR &amp;lt; 30 (vs. reference eGFR \u2265 90)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Kidney dysfunction in patients with HFpEF is characterized by more severe PVD at rest and with exercise, leading to reduced cardiac output reserve, impaired exercise capacity, and increased risk for adverse events. Further study is warranted to better understand causal relationships between CKD and PVD, and determine whether novel therapies to improve kidney function might target these impairments to improve clinical status.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejhf\/xuag140","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T11:33:13Z","timestamp":1777116793000},"source":"Crossref","is-referenced-by-count":2,"title":["Kidney dysfunction and pulmonary vascular disease in heart failure with preserved ejection fraction"],"prefix":"10.1093","author":[{"given":"Matthew B","family":"Amdahl","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 200 First Street SW, Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6210-7669","authenticated-orcid":false,"given":"Jwan A","family":"Naser","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 200 First Street SW, Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 200 First Street SW, Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Doi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 200 First Street SW, Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonari","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 200 First Street SW, Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Ibe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 200 First Street SW, Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M","family":"Testani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Yale University , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8921-7078","authenticated-orcid":false,"given":"Vojtech","family":"Melenovsky","sequence":"additional","affiliation":[{"name":"IKEM , Prague ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh N V","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 200 First Street SW, Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9375-0596","authenticated-orcid":false,"given":"Barry A","family":"Borlaug","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 200 First Street SW, Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"2026051207573918300_xuag140-B1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1161\/CIRCULATIONAHA.116.022249","article-title":"Heart failure with preserved ejection fraction: a kidney disorder?","volume":"134","author":"Fang","year":"2016","journal-title":"Circulation"},{"key":"2026051207573918300_xuag140-B2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ejhf.35","article-title":"The kidney in congestive heart failure: \u2018are natriuresis, sodium, and diuretics really the good, the bad and the ugly?\u2019: renal sodium handling in congestive heart failure","volume":"16","author":"Verbrugge","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026051207573918300_xuag140-B3","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ejhf.497","article-title":"Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation","volume":"18","author":"ter Maaten","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026051207573918300_xuag140-B4","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1093\/eurheartj\/ehs205","article-title":"The role of the kidney in heart failure","volume":"33","author":"Metra","year":"2012","journal-title":"Eur Heart J"},{"key":"2026051207573918300_xuag140-B5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.hfc.2021.03.005","article-title":"Renal dysfunction and heart failure with preserved ejection fraction","volume":"17","author":"Ananthram","year":"2021","journal-title":"Heart Fail Clin"},{"key":"2026051207573918300_xuag140-B6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10741-011-9261-3","article-title":"Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome","volume":"17","author":"Colombo","year":"2012","journal-title":"Heart Fail Rev"},{"key":"2026051207573918300_xuag140-B7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ihj.2017.01.005","article-title":"Pathophysiology of the cardio-renal syndromes types 1\u20135: an uptodate","volume":"69","author":"Di Lullo","year":"2017","journal-title":"Indian Heart J"},{"key":"2026051207573918300_xuag140-B8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1161\/CIRCULATIONAHA.106.678342","article-title":"Chronic kidney disease: effects on the cardiovascular system","volume":"116","author":"Schiffrin","year":"2007","journal-title":"Circulation"},{"key":"2026051207573918300_xuag140-B9","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1111\/j.1523-1755.2005.09906.x","article-title":"Chronic renal failure: a cardiovascular risk factor","volume":"68","author":"Fort","year":"2005","journal-title":"Kidney Int"},{"key":"2026051207573918300_xuag140-B10","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of Cardiovascular-Kidney-Metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"2026051207573918300_xuag140-B11","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.mayocp.2023.07.008","article-title":"Obesity, cardiorenal comorbidities, and risk of hospitalization in patients with heart failure with preserved ejection fraction","volume":"98","author":"Morgen","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"2026051207573918300_xuag140-B12","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1093\/eurheartj\/ehu254","article-title":"Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction","volume":"35","author":"Gori","year":"2014","journal-title":"Eur Heart J"},{"key":"2026051207573918300_xuag140-B13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/ejhf.445","article-title":"Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction: CKD and cardiac mechanics in HFpEF","volume":"18","author":"Unger","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026051207573918300_xuag140-B14","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jchf.2014.05.016","article-title":"Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction","volume":"2","author":"Katz","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026051207573918300_xuag140-B15","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/ejhf.821","article-title":"Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction: associations with and prognostic impact of CKD in HF","volume":"19","author":"L\u00f6fman","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026051207573918300_xuag140-B16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.cardfail.2020.01.003","article-title":"Renal dysfunction in heart failure with preserved ejection fraction: insights from the RELAX trial","volume":"26","author":"Patel","year":"2020","journal-title":"J Card Fail"},{"key":"2026051207573918300_xuag140-B17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288","article-title":"Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction: the TOPCAT trial","volume":"11","author":"Selvaraj","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026051207573918300_xuag140-B18","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.jacc.2025.03.009","article-title":"Interplay of chronic kidney disease and the effects of tirzepatide in patients with heart failure, preserved ejection fraction, and obesity: the SUMMIT trial","volume":"85","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026051207573918300_xuag140-B19","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1093\/eurheartj\/ehac184","article-title":"Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications","volume":"43","author":"Omote","year":"2022","journal-title":"Eur Heart J"},{"key":"2026051207573918300_xuag140-B20","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/eurheartj\/ehy809","article-title":"Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction","volume":"40","author":"Obokata","year":"2019","journal-title":"Eur Heart J"},{"key":"2026051207573918300_xuag140-B21","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.116.024822","article-title":"Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study","volume":"135","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"2026051207573918300_xuag140-B22","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J\u2014Cardiovasc Imaging"},{"key":"2026051207573918300_xuag140-B23","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026051207573918300_xuag140-B24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","article-title":"A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease","volume":"79","author":"Delgado","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2026051207573918300_xuag140-B25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/kisup.2012.77","article-title":"Summary of recommendation statements","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2026051207573918300_xuag140-B26","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nat Med"},{"key":"2026051207573918300_xuag140-B27","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.jchf.2015.06.014","article-title":"Prognostic value of estimated plasma volume in heart failure","volume":"3","author":"Duarte","year":"2015","journal-title":"JACC Heart Fail"},{"key":"2026051207573918300_xuag140-B28","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1177\/2045893217716108","article-title":"Pulmonary hypertension in patients with chronic kidney disease: invasive hemodynamic etiology and outcomes","volume":"7","author":"O\u2019Leary","year":"2017","journal-title":"Pulm Circ"},{"key":"2026051207573918300_xuag140-B29","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1053\/j.ajkd.2019.08.027","article-title":"Pulmonary hypertension subtypes and mortality in CKD","volume":"75","author":"Edmonston","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026051207573918300_xuag140-B30","doi-asserted-by":"publisher","first-page":"2401324","DOI":"10.1183\/13993003.01324-2024","article-title":"Definition, classification and diagnosis of pulmonary hypertension","volume":"64","author":"Kovacs","year":"2024","journal-title":"Eur Respir J"},{"key":"2026051207573918300_xuag140-B31","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1161\/CIRCULATIONAHA.117.031608","article-title":"Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction","volume":"137","author":"Fayyaz","year":"2018","journal-title":"Circulation"},{"key":"2026051207573918300_xuag140-B32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ccm.2020.11.002","article-title":"Pulmonary hypertension in left heart disease","volume":"42","author":"Reddy","year":"2021","journal-title":"Clin Chest Med"},{"key":"2026051207573918300_xuag140-B33","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/eurjhf\/hft060","article-title":"Venous congestion and renal function in heart failure \u2026 it\u2019s complicated","volume":"15","author":"Testani","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026051207573918300_xuag140-B34","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jacc.2009.03.074","article-title":"Venous congestion and worsening renal function","volume":"54","author":"Testani","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026051207573918300_xuag140-B35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1161\/CIRCULATIONAHA.109.933275","article-title":"Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival","volume":"122","author":"Testani","year":"2010","journal-title":"Circulation"},{"key":"2026051207573918300_xuag140-B36","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.116.022362","article-title":"Systemic consequences of pulmonary hypertension and right-sided heart failure","volume":"141","author":"Rosenkranz","year":"2020","journal-title":"Circulation"},{"key":"2026051207573918300_xuag140-B37","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1002\/ehf2.13534","article-title":"Haemodynamic parameters associated with renal function prior to and following heart transplantation","volume":"8","author":"Baudry","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026051207573918300_xuag140-B38","doi-asserted-by":"publisher","first-page":"2300844","DOI":"10.1183\/13993003.00844-2023","article-title":"RUNX2 is stabilised by TAZ and drives pulmonary artery calcification and lung vascular remodelling in pulmonary hypertension due to left heart disease","volume":"64","author":"Liu","year":"2024","journal-title":"Eur Respir J"},{"key":"2026051207573918300_xuag140-B39","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051207573918300_xuag140-B40","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial","volume":"84","author":"Pratley","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026051207573918300_xuag140-B41","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with Type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026051207573918300_xuag140-B42","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet Lond Engl"},{"key":"2026051207573918300_xuag140-B43","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1161\/CIRCULATIONAHA.119.045409","article-title":"Altered hemodynamics and End-organ damage in heart failure: impact on the lung and kidney","volume":"142","author":"Verbrugge","year":"2020","journal-title":"Circulation"},{"key":"2026051207573918300_xuag140-B44","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jamacardio.2024.1914","article-title":"Dapagliflozin and right ventricular\u2013pulmonary vascular interaction in heart failure with preserved ejection fraction: a secondary analysis of a Randomized Clinical Trial","volume":"9","author":"Reddy","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026051207573918300_xuag140-B45","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jacc.2011.02.055","article-title":"Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction","volume":"58","author":"Haykowsky","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026051207573918300_xuag140-B46","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1093\/eurjhf\/hft026","article-title":"Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction","volume":"15","author":"Abudiab","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026051207573918300_xuag140-B47","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1161\/CIRCULATIONAHA.117.029058","article-title":"Exercise intolerance in heart failure with preserved ejection fraction: diagnosing and ranking its causes using personalized O2 pathway analysis","volume":"137","author":"Houstis","year":"2018","journal-title":"Circulation"},{"key":"2026051207573918300_xuag140-B48","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jacc.2017.05.029","article-title":"Arterial stiffening with exercise in patients with heart failure and preserved ejection fraction","volume":"70","author":"Reddy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026051207573918300_xuag140-B49","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1161\/CIRCULATIONAHA.124.068788","article-title":"Dapagliflozin enhances arterial and venous compliance during exercise in heart failure with preserved ejection fraction: insights from the CAMEO-DAPA Trial","volume":"150","author":"Tada","year":"2024","journal-title":"Circulation"},{"key":"2026051207573918300_xuag140-B50","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","article-title":"Phenomapping for novel classification of heart failure with preserved ejection fraction","volume":"131","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"2026051207573918300_xuag140-B51","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.cardfail.2020.08.008","article-title":"Characterization of the progression from ambulatory to hospitalized heart failure with preserved ejection fraction","volume":"26","author":"Reddy","year":"2020","journal-title":"J Card Fail"},{"key":"2026051207573918300_xuag140-B52","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/ejhf.417","article-title":"Lung congestion in chronic heart failure: haemodynamic, clinical, and prognostic implications","volume":"17","author":"Melenovsky","year":"2015","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag140\/68168589\/xuag140.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag140\/68168589\/xuag140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:57:42Z","timestamp":1778587062000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article\/doi\/10.1093\/ejhf\/xuag140\/8663179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":52,"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag140","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"article-number":"xuag140"}}